Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.
Martini C, Logan JM, Sorvina A, Gordon C, Beck AR, S-Y Ung B, Caruso MC, Moore C, Hocking A, Johnson IRD, Li KL, Karageorgos L, Hopkins AM, Esterman AJ, Huzzell C, Brooks RD, Lazniewska J, Hickey SM, Bader C, Parkinson-Lawrence E, Weigert R, Sorich MJ, Tewari P, Martin C, O'Toole S, Bates M, Ward M, Mohammed B, Keegan H, Watson W, Prendergast S, Heffernan S, NiMhaolcatha S, O'Connor R, Malone V, Carter M, Ryan K, Brady N, Clarke A, Sokol F, Prabhakaran S, Stahl J, Klebe S, Samaratunga H, Delahunt B, Selemidis S, Moretti KL, Butler LM, O'Leary JJ, Brooks DA. Martini C, et al. Among authors: moretti kl. Pathology. 2023 Feb;55(1):40-51. doi: 10.1016/j.pathol.2022.08.001. Epub 2022 Aug 20. Pathology. 2023. PMID: 36089417 Free article.
Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1.
Logan JM, Hopkins AM, Martini C, Sorvina A, Tewari P, Prabhakaran S, Huzzell C, Johnson IRD, Hickey SM, Ung BS, Lazniewska J, Brooks RD, Moore CR, Caruso MC, Karageorgos L, Martin CM, O'Toole S, Bogue Edgerton L, Ward MP, Bates M, Selemidis S, Esterman A, Heffernan S, Keegan H, Ní Mhaolcatha S, O'Connor R, Malone V, Carter M, Ryan K, Clarke A, Brady N, Klebe S, Samaratunga H, Delahunt B, Sorich MJ, Moretti K, Butler LM, O'Leary JJ, Brooks DA. Logan JM, et al. Cancers (Basel). 2023 Jun 16;15(12):3215. doi: 10.3390/cancers15123215. Cancers (Basel). 2023. PMID: 37370825 Free PMC article.
Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers.
Logan JM, Martini C, Sorvina A, Johnson IRD, Brooks RD, Caruso MC, Huzzell C, Moore CR, Karageorgos L, Butler LM, Tewari P, Prabhakaran S, Hickey SM, Klebe S, Samaratunga H, Delahunt B, Moretti K, O'Leary JJ, Brooks DA, Ung BS. Logan JM, et al. Sci Data. 2024 Aug 8;11(1):852. doi: 10.1038/s41597-024-03696-0. Sci Data. 2024. PMID: 39117701 Free PMC article.
ISUP Group 4 - a Homogenous Group of Prostate Cancers?
Lu TC, Moretti K, Beckmann K, Cohen P, O'Callaghan M. Lu TC, et al. Pathol Oncol Res. 2018 Oct;24(4):921-925. doi: 10.1007/s12253-017-0331-2. Epub 2017 Oct 27. Pathol Oncol Res. 2018. PMID: 29079965 Free article.
Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR, O'Callaghan ME, Ruseckaite R, Kinnear N, Miller C, Evans S, Roder DM, Moretti K; South Australian Prostate Cancer Clinical Outcomes Collaborative. Beckmann KR, et al. BJU Int. 2017 Jun;119(6):862-871. doi: 10.1111/bju.13622. Epub 2016 Sep 3. BJU Int. 2017. PMID: 27489140
Prostate cancer outcomes and delays in care.
O'Callaghan ME, Shi Z, Kopsaftis T, Moretti K. O'Callaghan ME, et al. Int Urol Nephrol. 2017 Mar;49(3):449-455. doi: 10.1007/s11255-017-1508-z. Epub 2017 Jan 12. Int Urol Nephrol. 2017. PMID: 28083860
Satisfaction with care in men with prostate cancer.
Forgione M, Sara S, Vincent AD, Borg M, Moretti K, O'Callaghan ME. Forgione M, et al. Eur J Cancer Care (Engl). 2019 Jul;28(4):e13028. doi: 10.1111/ecc.13028. Epub 2019 Feb 27. Eur J Cancer Care (Engl). 2019. PMID: 30815942
57 results